Opzelura ^*

Opzelura may begin to improve eczema symptoms like itching within a few weeks, but full results can take up to eight weeks. For vitiligo, repigmentation is a slower process. Noticeable changes can take 24 weeks or more of consistent application. Results and timelines vary for each individual and their condition.

Opzelura can be used on the face for both eczema and vitiligo. However, you must be very careful to avoid applying it in or near your eyes, mouth, or inside your nose. Always apply a very thin layer only to the affected skin as directed by your healthcare provider to ensure safety.

Opzelura is not a steroid. It is a topical Janus kinase (JAK) inhibitor, which is a newer class of medication. It works by targeting specific pathways inside cells that cause skin inflammation. This mechanism is different from corticosteroids and avoids steroid-related side effects like skin thinning with long-term use.

If you miss a dose of Opzelura, you should apply it as soon as you remember. If it is already close to the time for your next dose, just skip the missed one. Do not apply a double dose to make up for the one you missed, as this can increase your risk of side effects.

Yes, moisturizers can and should be used while you are treating your skin with Opzelura, especially for atopic dermatitis. It is best to apply the moisturizer or emollient first. Wait for it to fully absorb into the skin before you apply the thin layer of Opzelura cream.

Opzelura effectively manages symptoms but does not provide a cure for eczema or vitiligo. For eczema, it helps control flare-ups by reducing itching and inflammation. For vitiligo, it helps restore skin pigment. The conditions may return if you stop treatment, so it is used for long-term management.

You should limit sun exposure on skin treated with Opzelura. While specific studies are limited, it is wise to protect treated areas from natural sunlight and artificial UV light from tanning beds. Use sunscreen and wear protective clothing over areas not being treated with the cream to be safe.

You should apply only a thin layer of Opzelura cream to the affected skin areas. For eczema, do not cover more than 20% of your body. For vitiligo, do not cover more than 10%. Following these guidelines is important for safety and helps prevent applying too much medication.

Opzelura should not be used by anyone with a known allergy to ruxolitinib. It is also not recommended for patients with active infections, low blood cell counts, or a history of tuberculosis. Women who are pregnant or breastfeeding should also avoid using it. Always discuss your medical history with your doctor.

Opzelura does have a boxed warning for potential serious side effects, which is a risk for all JAK inhibitors. These include serious infections, major cardiovascular events, blood clots, and certain cancers. While the risk from a topical cream is lower than oral pills, it is crucial to discuss this with your doctor.

Opzelura cream should be stored at room temperature, between 68°F to 77°F (20°C to 25°C). You must keep the tube tightly closed and stored away from moisture and direct heat. Do not put Opzelura in the refrigerator or freezer, as this can damage the medication.

The use of Opzelura with other topical prescription medications on the same area has not been studied. You should not use it with other JAK inhibitors, biologic immunomodulators, or strong immunosuppressants. Inform your doctor about all over-the-counter and prescription products you use on your skin to prevent interactions.

Opzelura does not currently have a generic version available on the market. The active ingredient is ruxolitinib, but the topical formulation is protected by patents. These patents prevent other manufacturers from creating a generic equivalent for several years. It is only available as the brand-name product.